Analyst Price Targets — MESO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 27, 2026 10:43 am | — | Piper Sandler | $39.00 | $16.84 | TheFly | Mesoblast price target raised to $39 from $35 at Piper Sandler |
| September 24, 2024 8:07 am | Jason McCarthy | Maxim Group | $12.00 | $6.74 | TheFly | Mesoblast upgraded to Buy at Maxim on Ryoncil opportunity |
| July 23, 2024 1:06 pm | Edward Tenthoff | Piper Sandler | $11.00 | $8.27 | StreetInsider | Piper Sandler Upgrades Mesoblast Limited (MESO) to Overweight |
Latest News for MESO
Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript
RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026). Chief…
Mesoblast NASDAQ: MESO reported $115 million in net revenue for fiscal 2026, its first full year of commercial sales for RYONCIL, the company's FDA-approved allogeneic mesenchymal stromal cell therapy for children with steroid-refractory acute graft-versus-host disease, or GVHD.
Mesoblast rises after completing treatment of 350 patients in a pivotal phase III study of rexlemestrocel-L for treating chronic low back pain.
Mesoblast Limited (NASDAQ:MESO) stock is trading higher on Monday after the company concluded patient dosing for its crucial Phase 3 clinical trial evaluating rexlemestrocel-L.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MESO.
U.S. House Trading
No House trades found for MESO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.